Hostname: page-component-5c6d5d7d68-7tdvq Total loading time: 0 Render date: 2024-08-24T16:48:36.653Z Has data issue: false hasContentIssue false

Phencyclidine, excitatory amino acids, psychiatry and drug abuse: Historical perspectives on clinical-laboratory interactions

Published online by Cambridge University Press:  18 September 2015

Extract

Some 40 years ago phencyclidine (PCP) was developed as the prototype of a proposed new class of ‘dissociative’ general anesthetics, so called because it induced a marked dissociation from the environment without complete loss of consciousness. In the earliest clinical trials of PCP anesthesia, it was observed that as many as half the subjects experienced severe psychotic reactions during and beyond emergence. This striking clinical observation at once marked the failure of PCP as a suitable general anesthetic, and the beginning of a remarkable new era in basic and clinical neuroscience which can serve as an example of the interaction between clinical observation and basic science. At once, clinical researchers turned their focus upon the characterization of the PCP-induced psychosis, and recognized striking similarities between PCP-induced symptoms and signs and both the negative and positive symptoms of schizophrenia, proposing the PCP psychosis as a new model of that illness. Several years later PCP suddenly emerged as a major drug of abuse, with the result that emergency rooms and psychiatric inpatient units were observing and treating large numbers of these patients, in many of whom a diagnosis of schizophrenia could not be ruled out until toxicological analyses were performed. This natural experiment yielded a huge amount of additional data, and contributed a strong public-health based impetus to research into the nature and treatment of PCP intoxication.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literature

1.Javitt, DC, Zukin, SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiat 1991; 148: 1301–08.Google ScholarPubMed
2.Vincent, JP, Kartalovski, B, Geneste, P, et al.Interaction of phencyclidine (‘angel dust’) with a specific receptor in rat brain membranes. Proc nati Acad Sci USA 1979;76:4678–82.CrossRefGoogle ScholarPubMed
3.Zukin, SR, Zukin, RS. Specific [3H] phencyclidine binding in rat central nervous system. Proc nati Acad Sci USA 1979;76:5372–6.CrossRefGoogle ScholarPubMed
4.Javitt, DC, Zukin, SR. Role of excitatory amino acids in neuropsychiatrie illness. J Neuropsychiatry clin Neurosci 1990;2:4452.Google ScholarPubMed
5.Javitt, DC, Zylberman, I, Zukin, SR, Heresco-Levy, U, Lindenmayer, J-P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiat 1994;151:1234–6.Google ScholarPubMed
6.Heresco-Levy, U, Silipo, G, Javitt, DC. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996;32:731–40.Google ScholarPubMed
7.Herman, BH, Vocci, F, Bridge, P. The effects of NMDA receptor antagonists and nitric oxide synthesis inhibitors on opioid tolerance and withdrawal: Medications development issues for opiate addiction. Neuropsychopharmacology 1995;13:269–93.CrossRefGoogle Scholar